Tracked deals
5
5 tracked deals across 2020-2026.
Public Company
Healthcare
UCB
Brussels, Belgium
Global biopharmaceutical company focused on severe central nervous system (neurology) and immunological conditions; purpose-driven to deliver meaningful solutions that go beyond medicine.
- Focus Areas
- Immunology, Central Nervous System (Neurology), Biopharmaceuticals
- Website
- ucb.com
Recent pace
3
3 tracked deals announced in the last 12 months.
Deal mix
Buyout
5 buyout
UCB Acquisition Volume by Year
Last 3 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- UCB
- Target
- Candid Therapeutics
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
UCB, a global biopharmaceutical company, has signed a definitive agreement to acquire Candid Therapeutics for up to $2.2 billion. The deal includes $2.0 billion in upfront payments and up to $200 million in potential milestone payments, and is expected to close by the end of Q2 or early Q3 2026, subject to antitrust clearance and customary conditions.
-
May 3, 2026
- Buyer
- UCB
- Target
- Candid Therapeutics
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
UCB has agreed to acquire Candid Therapeutics, a clinical-stage biotechnology company focused on T-cell engagers for autoimmune and inflammatory diseases, for up to $2.2 billion including $2.0 billion upfront. Two River and Vida Ventures, part of the Bellco Health ecosystem, highlighted their roles in founding and early development of Candid following the announced acquisition.
-
April 21, 2026
- Buyer
- UCB
- Target
- Neurona Therapeutics
- Industry
- Healthcare Services
- Location
- Belgium
- Type
- Buyout
UCB announced a definitive agreement to acquire Neurona Therapeutics in a deal valued at up to $1.15 billion, including $650 million upfront and up to $500 million in potential milestone payments. The acquisition is intended to strengthen UCB’s epilepsy portfolio and expand it into regenerative medicine via Neurona’s lead cell therapy, NRTX-1001.
-
January 19, 2022
- Buyer
- UCB, Zinc Merger Sub, Inc.
- Target
- Zogenix, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.
-
June 5, 2020
- Buyer
- UCB
- Target
- Engage Therapeutics
- Industry
- Pharmaceuticals
- Location
- New Jersey, United States
- Type
- Buyout
Belgium-based biopharma UCB has acquired Summit, New Jersey-based Engage Therapeutics for an upfront cash payment of US$125 million plus up to US$145 million in milestone payments, gaining worldwide rights to Staccato Alprazolam. The acquisition adds a late-stage, drug-device rescue therapy candidate for epilepsy to UCB's neurology portfolio and includes updated license and supply agreements with Alexza Pharmaceuticals.
Related Acquisition Pages
Selling a company? Get in front of buyers like UCB
Turn tracked acquisition activity into an outreach-ready buyer list.